BPC-157 Dosage: What a Dose Would Require

Every BPC 157 dosage figure in wide circulation traces back to animal work, most of it rat work, and none of it to a completed human efficacy trial. The numbers are real in the narrow sense that they appear in published experiments. They are not doses in the sense a pharmacologist uses the word: a quantity, by a stated route, in a stated species, chosen because a dose response relationship was characterised and a window between effect and harm was identified. For this compound, most of that chain stops at the rat.

That distinction is the subject of this article. It is not caution for its own sake. The number people are looking for does not yet exist in the form the question assumes it does.

Where the circulating numbers came from, and in which species

The published efficacy literature on BPC-157 is overwhelmingly rat and cell culture work, covering tendon, ligament, muscle and gut outcomes, and much of it comes from a small number of research groups. When a figure surfaces on a forum or a supplier page, it has usually been lifted from one of those rat experiments and then converted, by an allometric scaling rule, into something shaped like a human quantity.

Allometric scaling is a legitimate tool. Regulators expect to see it when a sponsor proposes a first in human starting dose. What it produces, though, is a starting point for a safety study. It carries no claim that the scaled quantity will do anything useful in a person. The conversion assumes that absorption, distribution, metabolism and clearance scale predictably with body size, and for peptides that assumption is exactly where models tend to break, because peptidase activity, plasma half life and tissue distribution can differ between species in ways body weight does not predict.

A scaled number is therefore a hypothesis about exposure. It is not a finding, and it should not be quoted as one.

Why a BPC 157 dosage cannot be read off a rat study

Three specific gaps sit between a rat experiment and a human dose.

The first is the endpoint. A rat tendon or gut study usually finishes with a mechanical test, a histological score, or a measurement made on excised tissue. Those endpoints are terminal. They are unavailable in a living person, which means the quantity that produced them cannot be tied to anything a human would experience or a clinician would measure.

The second is the route. Much of the animal work uses intraperitoneal or intragastric administration in rats. Neither maps cleanly onto what people describe doing. Intraperitoneal delivery has no routine human equivalent, and intragastric delivery in a rat is not the same event as a capsule swallowed by a human, whose stomach contents, transit time and enzyme profile differ.

The third is the absence of a published human pharmacokinetic profile. Without knowing how much of an administered quantity reaches circulation in a person, how long it persists, and how it is cleared, there is no arithmetic that converts a rat quantity into a human one with any defensible error bar.

What a quantity has to satisfy before it counts as a dose

The table below sets out the components of a dose recommendation and the state of each for this compound. The organism column matters: it records the species the supporting evidence actually came from, which is the detail most commonly dropped when a figure is repeated.

Read down the middle column. Every row that would be needed to justify a human quantity is either absent from the public record or was answered in a species that cannot stand in for a person on this question.

Route and formulation are part of the number, not a footnote

A quantity without a route is not a dose. A peptide given by injection and the same peptide swallowed are, pharmacologically, two different exposures, and the difference is not a small correction factor.

This matters here because oral use is widely described, while the animal literature that gives the compound its reputation used routes chosen for experimental convenience in rats. Any claim that an oral quantity produces the effects seen in those rat studies requires oral bioavailability data in humans, and that data is not in the public record. The claim is not disproved. It is unsupported, which is a different status and should be reported as such.

Formulation compounds the problem. Peptide content, purity and stability vary between preparations sold as research chemicals, and a quantity stated on a label describes what was intended, not necessarily what is present.

The registered human trials, and what they are built to settle

Human trials do exist and are registered. NCT07803250 is a Phase 1 study in recovery after rotator cuff repair, listed with 30 participants and not yet recruiting. NCT02637284 is a Phase 1 safety and pharmacokinetics study listed with 42 participants, with status unknown.

Registered, completed and published are three separate states, and only the third puts numbers into the public record. A registration is a description of an intention. It tells you a protocol was written and filed. It does not tell you the study finished, that the results supported the hypothesis, or that anyone outside the sponsor has seen them.

If those studies complete and publish, the Phase 1 work is the part that would begin to answer the dosing question, because Phase 1 is where pharmacokinetics and tolerability in humans are characterised. A Phase 2 efficacy signal without that groundwork would still leave the quantity poorly specified.

Purity, quantity and potency are three separate measurements

A certificate of analysis is often produced as though it answered the dose question. It does not, and the reason is worth stating precisely.

A purity assay, typically by high performance liquid chromatography, reports the proportion of the material that is the intended peptide rather than truncated sequences, deletion products or residual synthesis reagents. It describes composition. It says nothing about how much peptide is in the vial, which is a quantity measurement, usually by weight or by amino acid analysis. And neither measurement says anything about potency, which is a biological property established in an assay against a defined endpoint.

Material can be highly pure, present in less quantity than the label states, and biologically untested, all at once. Treating a purity figure as reassurance about a dose confuses an analytical result with a pharmacological one.

The practical consequence runs further than it first appears. Any arithmetic a person performs after reconstituting a vial takes the labelled quantity as its starting input. If that input is wrong, every figure derived from it is wrong by the same factor, and the calculation itself will look entirely correct. Precision downstream of an unverified number produces confidence rather than accuracy. This is also why comparisons across suppliers, or across batches from one supplier, are unreliable in principle: two vials bearing the same label are not established to contain the same amount of the same substance unless each was assayed, and assays are batch specific rather than a permanent property of a product line.

None of that is an argument that suppliers are dishonest. It is an argument that the checks which normally sit behind a labelled quantity, from manufacturing standards to independent release testing, are part of medicines regulation, and a compound outside that system does not inherit them.

Related reading on this compound: [what the published protocols ran](/research/guides/bpc-157-protocol), [what BPC-157 actually is](/research/guides/what-is-bpc-157), [whether cycling applies here](/research/guides/bpc-157-cycle).